Pharmaceuticals, Biotechnology & Life Sciences

Explore Eli Lilly’s 2026 outlook—higher sales and steady EPS—driven by its powerful injectable weight‑loss and diabetes therapies, and insights on market dynamics.

West Pharmaceutical Services tops Q3 2026 expectations, boosts 2026 outlook, and expands high‑value HVP components and microneedle tech for injectable therapeutics.

Explore how Eisai’s lecanemab drives Alzheimer’s therapy growth with real‑world data, subcutaneous dosing, and value‑based reimbursement, boosting global sales and market share.

Rule 144 filings reveal Natera executives selling RSUs, offering insights into insider confidence and liquidity dynamics in the competitive genomic testing market.

Institutional investors boost ABIVAX SA stake, signalling strong confidence in its biotech pipeline and growth prospects.

Explore Bayer’s shift to biologically‑based crop protection and nitrogen‑fixation tech, boosting yields and sustainability while positioning it for future growth.

Discover why Novo Nordisk remains a top choice for investors in obesity & diabetes, with strong margins, a robust pipeline, and strategic pricing that beats rivals.

EU approval of Enhertu gives Daiichi Sankyo a breakthrough 50% IDFS advantage for early‑stage HER2‑positive breast cancer, unlocking €144 m potential sales and a new oncology frontier.

Syngene International reports a 13% Q2 revenue lift driven by biologics CDMO growth, AI‑powered discovery, and its first U.S. manufacturing deal, boosting margins and global reach.

Roivant Sciences sees board shares boost and BlackRock’s stake over 8%—signaling tighter governance, stronger investor alignment, and growth‑ready biotech strategy.